Search Results for 'cell therapy'

1 results found.

REMEDI enters agreement with US company to advance research into diabetic foot ulcers

REMEDI, The Regenerative Medicine Institute at NUI Galway and Orbsen Therapeutics have entered into an agreement with Cardium Therapeutics to utilise Cardium’s Excellagen® pharmaceutically-formulated gel as a delivery agent for Orbsen Therapeutics’ proprietary stromal cell therapy in pre-clinical studies for the potential treatment of diabetic foot ulcers.

 

Page generated in 0.0367 seconds.